Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
goserelin + docetaxel + prednisone
- Development stage
- Unknown
- Lead developer
- The Second Hospital of Tianjin Medical University
- Modality
- Small Molecules, Peptides
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Luminal type-1 is a combination regimen consisting of goserelin, docetaxel, and prednisone. It is evaluated in the Phase 2 STAMP clinical trial (NCT03696186), sponsored by the Second Hospital of Tianjin Medical University, which investigates molecular subtype-guided therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). In this trial, patients are classified into molecular subtypes (luminal, neuroendocrine, or atypical) based on immunohistochemical markers. Patients with the luminal phenotype randomized to the standard treatment arm receive the "Luminal type-1" regimen, which consists of goserelin (3.75 mg once every 4 weeks), docetaxel (75 mg/m2 on day 1 every 3 weeks), and prednisone (5 mg twice daily).
- Other names
- goserelin/docetaxel/prednisoneLuminal type-1
02
Targets
GR (Glucocorticoid receptor)GnRHR (Gonadotropin-releasing hormone receptor)MR (Mineralocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on goserelin + docetaxel + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on goserelin + docetaxel + prednisone.